SAN DIEGO, March 22, 2016 /PRNewswire/ -- Molecular Response, LLC (MRL), a privately held biotechnology company that acquired one of world's largest living tumor biobanks in 2010, announced today the expansion of their state-of-the-art biobank facility in San Diego, California. Molecular Response will now offer biorepository storage services to external clients.
"With the expansion of our facilities at Torrey Pines Science Park, our liquid nitrogen and -80oC biospecimen storage capacities have increased by 5-fold, and we installed a 3,000 liter microbulk nitrogen tank to supply the new liquid nitrogen vapor (LN2) freezers. Now, with our already existing industry gold standard cold chain custody processes, we can offer FDA Title 21 CFR Part 11 compliant biospecimen storage options to external clients," said Dr. Brett Hall, Chief Executive Officer for the Company. "Our biorepository capacity exceeds 500,000 vials each for liquid nitrogen vapor and -80oC. For clients with large biospecimen storage needs, we could readily expand the biobank footprint to provide capacities exceeding 2 million vials."
"It was a logical step for our company to offer biorepository services, as biobanking has been core to the company's mission since its inception. Molecular Response, in conjunction with Oncotech beforehand, has successfully maintained a large, viable sample tumor biobank for over 20 years," said Dr. Hall.
About the Molecular Response Biobank and Biorepository
The Molecular Response Tumor Biobank contains over 130,000 viably frozen, whole, disaggregated tumors that cover more than 40 cancer indications. In addition, the biobank contains approximately 250,000 histology slides and thousands of formalin-fixed paraffin-embedded (FFPE) tumor tissue blocks.
The Molecular Response Biorepository has an overall capacity in excess of 1.2 million LN2 cryovials and -80oC vials. With under twenty percent sequestered for existing biobanking activities, the available biostorage capacity is over one million LN2 cryovials and -80oC vials.
About Molecular Response
Molecular Response maintains a state-of-the-art biobank facility and utilizes intelligently-designed tumor models to discover novel oncology drugs. Our goal is to capitalize on advanced human biologic platforms with clinically relevant molecular response and biomarker data to accelerate novel or improved therapeutic drug development processes and programs. For additional information please visit our website: www.molecularresponse.com.
SOURCE Molecular Response